aTyr Pharma to Participate in April Investor Conferences

Rhea-AI Summary

aTyr Pharma (Nasdaq: ATYR), a clinical stage biotechnology company, has announced its participation in two major investor conferences in April 2025. The company will attend the Jones Healthcare and Technology Innovation Conference in Las Vegas (April 8-9) and the Piper Sandler Spring Biopharma Symposium in Boston (April 17), both featuring one-on-one investor meetings.

aTyr specializes in developing first-in-class medicines using their proprietary tRNA synthetase platform. Their lead product, efzofitimod, is a first-in-class biologic immunomodulator being developed for interstitial lung disease treatment. The company's innovative approach involves leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation, focusing on novel domains that regulate extracellular pathways in humans.

News Market Reaction

-5.74%

1 alert

-5.74% News Effect

On the day this news was published, ATYR declined 5.74%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2025.

Details of the conferences appear below:

Conference: Jones Healthcare and Technology Innovation Conference
Date: April 8 – 9, 2025
Location: Las Vegas, NV
Format: 1x1 Investor Meetings

Conference: Piper Sandler Spring Biopharma Symposium
Date: April 17, 2025
Location: Boston, MA
Format: 1x1 Investor Meetings

For more information on how to register, please contact your Jones or Piper Sandler representative.

About aTyr

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.

Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
adunston@atyrpharma.com

FAQ

What investor conferences will aTyr Pharma (ATYR) attend in April 2025?

aTyr Pharma will attend two conferences: the Jones Healthcare and Technology Innovation Conference in Las Vegas (April 8-9) and the Piper Sandler Spring Biopharma Symposium in Boston (April 17).

What is aTyr Pharma's (ATYR) lead therapeutic candidate?

aTyr's lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in development for treating interstitial lung disease.

What is the focus of aTyr Pharma's (ATYR) discovery platform?

aTyr's platform focuses on unlocking therapeutic intervention points by uncovering signaling pathways driven by domains derived from all 20 tRNA synthetases.

What medical conditions does aTyr Pharma (ATYR) target with their therapies?

aTyr develops therapies targeting fibrosis and inflammation, specifically focusing on interstitial lung disease, which involves immune-mediated disorders causing lung inflammation and scarring.